Jacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement

Stock News

10/28

Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.

ULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.

This licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174469961"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174469961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174469961?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174469961","market":"us","top_or_hot":-1,"title":"Jacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement","media":"Stock News","content":"<p>Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.</p>\n<p>ULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.</p>\n<p>This licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobson Pharma (02633) and JBM Healthcare (02161): ULFERTS and ULFERTS (Hong Kong) Enter into 2025 Licensing Agreement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-28 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.</p>\n<p>ULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.</p>\n<p>This licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1201","symbol_name":"家庭裝飾零售","start_time":0,"source_url":"","article_id":"1174469961","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174469961","pubTimestamp":1761648507,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1201":"家庭装饰零售","02633":"雅各臣科研制药","BK1606":"中医药概念","BK1191":"制药","02161":"健倍苗苗","BK1585":"昨日强势股","01711":"欧化"},"translate_title":"雅各臣药业(02633)与健邦医疗(02161)：ULFERTS与ULFERTS(香港)订立2025年许可协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01711":1,"02161":1,"02633":1},"content_text":"Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that as the 2020 licensing agreement is set to expire on November 30, 2025, ULFERTS and ULFERTS (Hong Kong) entered into the 2025 ULFERTS Licensing Agreement on October 28, 2025. Under the agreement, ULFERTS has agreed to license part of its factory to ULFERTS (Hong Kong) from December 1, 2025, to January 27, 2028 (inclusive), with a monthly licensing fee of HK$247,000.\nULFERTS Limited is an indirect wholly-owned subsidiary of Jacobson Pharma, while ULFERTS (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM Healthcare. Since 2007, ULFERTS has leased the factory from the Science Park for pharmaceutical manufacturing. Under the lease terms, ULFERTS may license certain entities to use the factory with prior written approval from the Science Park.\nThis licensing arrangement under the 2025 ULFERTS Licensing Agreement enables ULFERTS to generate rental income from unused factory space while providing ULFERTS (Hong Kong) with a suitable manufacturing site. Relocating ULFERTS (Hong Kong)'s existing Good Manufacturing Practice (GMP)-compliant facilities would be costly and time-consuming. Therefore, the 2025 agreement allows ULFERTS (Hong Kong) to avoid operational disruptions and relocation expenses.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}